Babcock Luke, Singer Samantha R, Carbiener Pamela
Family Medicine, Halifax Health Medical Center, Daytona Beach, USA.
Obstetrics and Gynecology, Florida State University College of Medicine, Tallahassee, USA.
Cureus. 2023 Jul 26;15(7):e42481. doi: 10.7759/cureus.42481. eCollection 2023 Jul.
Evidence suggests that IL-17, a pro-inflammatory cytokine, suppresses tumor carcinogenesis; therefore, the use of IL-17 inhibitors accelerates carcinoma growth. We present a case of a perimenopausal female who was diagnosed with synchronous primary ovarian and endometrial endometrioid carcinoma following the use of secukinumab, a monoclonal antibody against IL-17. After eight months of secukinumab, she developed progressive vaginal bleeding, left upper quadrant pain, and abdominal distention. CT imaging displayed a large abdominal mass, and biopsies produced the diagnosis. It is proposed that by inhibiting IL-17, carcinogenesis was expedited. This case highlights a relationship between secukinumab and accelerated carcinogenesis. Consequently, due to the incidence of endometrial carcinoma and the morbidity rate of ovarian carcinoma, individuals taking IL-17 inhibitors may need prophylactic screening and close monitoring.
有证据表明，促炎细胞因子白细胞介素-17（IL-17）可抑制肿瘤发生；因此，使用IL-17抑制剂会加速癌症生长。我们报告一例围绝经期女性病例，该患者在使用抗IL-17单克隆抗体司库奇尤单抗后，被诊断为同时性原发性卵巢和子宫内膜样癌。使用司库奇尤单抗8个月后，她出现进行性阴道出血、左上腹疼痛和腹胀。CT成像显示腹部有一个大肿块，活检确诊。据推测，通过抑制IL-17，癌症发生加快。该病例突出了司库奇尤单抗与加速癌症发生之间的关系。因此，鉴于子宫内膜癌的发病率和卵巢癌的发病率，服用IL-
